创新的临床前数据使用来干预肺纤维化症的演变
Karina Smidt Simon1, Luísa Coutinho Coelho1, Paulo Henrique de Holanda Veloso1
1Department of Cellular Biology, Institute of Biological Sciences, University of Brasilia, Brasilia 70910-900, Brazil.
International journal of molecular sciences
|July 14, 2023
概括
新的免疫调节,ToAP3和ToAP4,显示出控制实验性异常性肺纤维化 (IPF) 的希望. 这些酸有助于维持小鼠模型中的肺组织特征和功能,为IPF提供了潜在的新疗法.
科学领域:
- 肺部医学 肺部医学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 异形性肺纤维化 (IPF) 是一种进展性和致命的肺部疾病,其机制尚不清楚,阻碍了有效的治疗开发.
- 目前IPF的治疗选择有限,强调需要新的治疗策略.
研究的目的:
- 研究免疫调节的潜力,特别是ToAP3和ToAP4,作为慢性肺纤维化治疗的替代疗法.
- 评估ToAP3和ToAP4在白血素 (BLM) 诱导的肺纤维化小鼠模型中的疗效.
主要方法:
- 在BALB/c小鼠中建立了一种慢性肺纤维化模型,使用内白菌素 (BLM) 灌注.
- 在BLM灌注后的第5天开始,小鼠接受了ToAP3和ToAP4的治疗,在第30天进行了分析.
- 评估包括ELISA,qPCR,形态评估和呼吸功能测试.
主要成果:
- ToAP3和ToAP4治疗延迟了由BLM引起的炎症和纤维化过程.
- 酸处理减轻了 I,III 和 IV 原生产的变化,并保留了通风机械.
- 基因表达模式表明了ToAP3和ToAP4的不同作用机制,这两种都调节了纤维化关联细胞因子的产生.
结论:
- 免疫调节ToAP3和ToAP4在小鼠模型中有效控制了实验IPF.
- 这些可以维持肺组织的完整性和功能,同时调节关键的纤维化通路.
- ToAP3和ToAP4代表了潜在的治疗替代品或辅助剂,用于管理异常性肺纤维化.
相关概念视频
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
218
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
218
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
202
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
202